Canada· CA-DIN-00213071
COSMEGEN
A dactinomycin product containing dactinomycin, registered in Canada by RECORDATI RARE DISEASES CANADA INC. The same ATC class is registered in 7 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Dactinomycin is registered in 7 of 19 countries.
Countries holding a registration under ATC L01DA01 (dactinomycin), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 4 of them publish a price we can compare per daily dose
Dactinomycin · ATC L01DA01
7 / 19 countries
- Canada
- Finlandprice
- Franceprice
- Germany
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- DACTINOMYCIN
- Manufacturer
- RECORDATI RARE DISEASES CANADA INC
- Country
- Canada (CA)
- ATC code
- L01DA01
- ATC class
- Dactinomycin
- Defined daily dose
- 0.32 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
163 interactions on record for dactinomycin.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dactinomycin · interactions on record
163 records
- 30 severe
- 83 moderate
- 15 minor
- 35 info
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dactinomycin in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesdactinomycinXGen Pharmaceuticals DJB, Inc.
- FinlandCosmegenLundbeck Pharmaceuticals Ireland Limited
- FranceCOSMEGEN 0,5 mg, poudre pour solution injectableRECORDATI RARE DISEASES
- GermanyLyovac-CosmegenRecordati Rare Diseases
- JapanアクチノマイシンＤノーベルファーマ
- NorwayLyovac-CosmegenOrphan Europe
- United KingdomCosmegen Lyovac 500microgram powder for solution for injection vialsRecordati Rare Diseases UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Germany · Lyovac-Cosmegen
- France · Cosmegen
- Italy · Cosmegen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ca147810-9695-41cd-92ea-54f6cb18fcf4 GET /v1/drugs/ca147810-9695-41cd-92ea-54f6cb18fcf4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "00213071",
"form": "POWDER FOR SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01DA01",
"schedule": [
"Prescription"
],
"drug_code": "250",
"strengths": [
"0.5 MG"
],
"ahfs_class": null,
"substances": [
"DACTINOMYCIN"
],
"product_categorization": null
}See everything about dactinomycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.